5 Conclusions
We demonstrated that empagliflozin inhibited chondrocytes ECM degradation, inflammation and cellular senescence in vitro and prevented cartilage degeneration in vivo by suppressing the NF-κB pathway activation. Our findings indicate a therapeutic potential of empagliflozin in OA treatment.